Partnering with

MOGRIFY

Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, in vivo reprogramming and ex vivo cell therapy to develop treatments for indications of high unmet clinical need. We are particularly interested in speaking with those with interest in ophthalmology, immuno-oncology, as well as other areas of degenerative disease where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development and co-development partnerships, as well as the exploration and generation of novel therapeutic modalities.

Current

PARTNERS

Sangamo Therapeutics

Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering.

Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells

MRC Laboratory of Molecular Biology

MRC Laboratory for Molecular Biology

The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, they provide knowledge needed to solve key problems in human health.

Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Duke-NUS Medical School

Duke-NUS Medical School

Duke-NUS Medical School is a research powerhouse and our distinguished scientists are transforming the way we understand, diagnose and treat diseases. Our founder, Assistant Professor, Owen Rackham, and his group at the School focus on what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. Developing methods that leverage the large volume of gene expression, epigenetic and interaction data that is being generated to develop biological hypotheses about how certain perturbations can influence cell fate.

Monash University

Monash University

The Polo Laboratory, a part of the Monash Biomedicine Discovery Institute at Monash University, focuses on the transcriptional and epigenetic mechanisms that govern cell identity, in particular, pluripotency and the reprogramming of somatic cells into induced pluripotent stem (iPS) cells.

Our

PIPELINE

AREA Sample Acquisition Bioinformatics In vitro PoC In vivo PoC IND Clinical Marketing
Immunotherapy (Oncology) mogrify mogrify mogrify mogrify partner partner
Ophthalmology (Retinal) mogrify mogrify mogrify partner partner
Collaborations (Pulmonary, Metabolic & Others) mogrify mogrify mogrify partner partner partner partner
mogrify Mogrify Progress partner Expect to Partner

Upcoming

Events & Conferences

28 November
-
1 December 2021
Region:
Europe
Attendee:
Pepe Ballester, Senior Scientist, Mogrify
Presentation title:
Presentation date:
Booth:

The British Society for Immunology Congress 2021, the annual flagship event, will take place from 28 November to 1 December 2021 in Edinburgh, UK.

11 December
-
14 December 2021
Region:
US
Attendee:
Louise Modis, CSO, David Matthews, Director of R&D, and Chris Oliphant, Manager of Immunology
Presentation title:
Presentation date:
Booth:

The American Society of Hematology (ASH) Annual Meeting & Exposition is the annual premier event in malignant and non-malignant hematology.

12 January
-
14 January 2022
Region:
Virtual Conference(s)
Attendee:
Rodrigo Santos, Director of Cell Technologies
Presentation title:
Presentation date:
Booth:

The ISSCR Stem Cells and Regenerative Medicine meeting will highlight topics from cell fate and pluripotency to disease modeling and clinical translation of cell therapies, dissecting the role of stem cells in basic biology and therapeutics alike.